Welcome : Guest

Bellicum Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Bellicum Pharmaceuticals, Inc., which is principally a Clinical-Stage Biopharmaceutical Company. Illustrated with 66 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-63852
Price: $3300
Company Type: Public
Pages: 69
Date: March 2017
Market Data Tables: 66

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Biologics......4
Table 1: No. of Biologics in Development by Therapeutic Area Worldwide (2015) - Percentage Market Share Breakdown for Autoimmune Disorders, Blood Disorders, Cancer/ Related Conditions, Cardiovascular Disease, Diabetes/Related Conditions, Digestive Disorders, Eye Conditions, Genetic Disorders, Infectious Diseases, Musculoskeletal Disorders, Neurologic Disorders, Respiratory Disorders, Skin Diseases, Transplantation, and Others......4
Table 2: Biologics Market by Component Worldwide (2015) - Percentage Share Breakdown by Value for Insulin, Multiple Sclerosis, Oncology, Tumor Necrosis Factor, and Others......5
Stem Cell Transplantation......6
Table 3: Adult Recipients (18+ years) Transplant Market by Cell Source in Japan (2015) - Percentage Share Breakdown by Volume for Bone Marrow, Cord Blood and Peripheral Blood Stem Cells......6
Table 4: Stem Cell Transplantation Market by Category for American Indian and Alaskan Natives in the US (2015) - Percentage Market Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......7
Table 5: Stem Cell Transplantation Market by Category for Asians in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......8
Table 6: Stem Cell Transplant Market by Category for Black and African Americans in the US (2015) - Percentage Market Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......9
Table 7: Stem Cell Transplantation Market by Category for Native Hawalian and Other Pacific Islanders in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......10
Table 8: Stem Cell Transplantation Market by Category for Whites in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......11
Haematopoietic Stem Cell Transplantation (HSCT)......12
Table 9: Haematopoietic Stem Cell Transplantation (HSCT) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union, United States and Rest Of World......12
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)......13
Table 10: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Leukemia by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......13
Table 11: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Bone Marrow Failure by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......14
Table 12: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Leukemia by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......15
Table 13: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Leukemias by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......16
Table 14: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Lymphoma by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......17
Table 15: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Lymphoproliferative by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......18
Table 16: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS) by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......19
Table 17: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Non-Malignant Disorders by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......20
Table 18: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Plasma Cell Disorders by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......21
Table 19: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Solid Tumors by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......22
Table 20: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Market by Category in Americas (2015) - Percentage Share Breakdown by Value for Acute Leukemia, Chronic Leukemia, Leukemias, Lymphoma, Lymphoproliferative, Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS) and Others......23
Table 21: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Market by Category in Europe (2015) - Percentage Share Breakdown by Value for Acute Leukemia, Leukemias, Lymphoma, Lymphoproliferative, Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS), Non-Malignant Disorders and Others......24
Table 22: Number of β-thalassemia Patients for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) by Category in Europe (2015) - Percentage Market Share Breakdown by Volume for Bone Marrow (BM), Mixed Chimerism, Peripheral Blood (PB), Unrelated Cord Blood Transplantation (UCB) and Uterine Natural Killer (UNK)......25
Bone Marrow Transplantation......26
Table 23: Bone Marrow Transplantation by Region Worldwide (2015) - Percentage Market Share Breakdown by Volume Sales for US, and Others......26
Cell Therapy......27
Table 24: Therapeutic Development Market by Product Worldwide (2015) - Percentage Share Breakdown by Volume for Cell Therapy, Monoclonal Antibodies, Vaccines and Others......27
Table 25: Biotechnology Drugs by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Cell Therapy, Gene Therapy, Monoclonal Antibodies (MAB), Recombinant Hormones and Proteins, Vaccines, and Others......28
Orphan Drugs......29
Table 26: Specialty Pharma & Orphan Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Europe, US and Rest of the World......29
Cancer Drugs......30
Table 27: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......30
Table 28: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......31
Cancer Market......32
Table 29: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......32
Table 30: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......33
Table 31: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......34
Table 32: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......35
Table 33: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......36
Table 34: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......37
Table 35: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......38
Table 36: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......39
Cancer Patients......40
Table 37: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......40
Table 38: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......41
Table 39: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......42
Table 40: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......43
Table 41: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......44
Table 42: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......45
Table 43: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......46
Table 44: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......47
Table 45: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......48
Table 46: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......49
Table 47: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......50
Table 48: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......51
Table 49: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......52
Hematological Cancer......53
Table 50: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......53
Chronic Myelogenous Leukemia (CML)......54
Table 51: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......54
Multiple Myeloma......55
Table 52: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......55
Table 53: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......56
Immunotherapy......57
Table 54: Immunotherapy Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union, United States and Rest of the World......57
Table 55: Immunotherapy Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Subcutaneous, and Sublingual......58
Table 56: No. of Patients for Immunotherapy by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Europe, North America, and Others......59
Table 57: No. of Patients for Immunotherapy by Age Group in the US (2015) - Percentage Market Share Breakdown by Value for 0-4 Patient Pool, 10 - 14 Patient Pool, 15 - 19 Patient Pool, 5-9 Patient Pool, Adult Patient Pool (over 65), and Adult Patient Pool (under 65)......60
Orphan Disease Therapeutics......61
Table 58: Market Shares of Leading Orphan Disease Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Pfizer, Inc., Sanofi S.A., and Others......61
Cancer Drugs......62
Table 59: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......62
Table 60: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......63
Table 61: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......64
Table 62: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......65
Table 63: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......66
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......67
Table 64: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......67
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......68
Table 65: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......68
Table 66: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......69